Neuropsychiatric Drug Development Summit on September 09-11, 2025 in Boston, United States

2025 continues to deliver progress, fueled by innovations in new mechanisms of action to improve neurotransmission, promote neuroplasticity, alleviate side effects, and more. However, as unmet needs rise and inherent challenges of heterogeneity, translatability, and placebo responses remain largely unresolved, the field is left to wonder: was Cobenfy just a ‘one-off’, or are we on the verge of a new wave of transformative approvals?

Uniting 150+ discovery, preclinical, translational, clinical, and regulatory leaders, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications.

Recognized by key leaders as the "ideal size", offering a "targeted audience" perfect for meaningful networking and collaboration, join thought leaders from Bristol Myers Squibb, AbbVie, Otsuka, Johnson and Johnson, Biogen, Lundbeck, Delix Therapeutics, Boehringer Ingelheim and many more this September to revitalize the mental health drug development landscape.

URLs:

Tickets: https://go.evvnt.com/3129393-2?pid=10008

Brochure: https://go.evvnt.com/3129393-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - Conference + Workshop Day: USD 3497.00,

Drug Developer Pricing - Conference Only: USD 2599.00,

Service Provider Pricing - Conference + Workshop Day: USD 4797.00,

Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Jessica Ash, Director of Digital Health, R AND D, Otsuka , Sam Benezra, Senior Scientist, Neural Circuits Group, Biogen, Dan Bonner, Co-Founder and Senior Vice President, Platform, Seaport Therapeutics, Michael Bowen, CSO, Kinoxis Therapeutics , Stephen Brannan, Consultant, Karuna Therapeutics, Alastair Brown, Senior Vice President, Translational Medicine, Nxera Pharma , Heramb Chadchankar, Senior Director and Head of Translational Science, Kynexis Therapeutics , James Cronican, Head of Translational Medicine and Clinical Pharmacology Neuroscience and Mental Health, Boehringer Ingelheim , Suresh Durgam, Chief Medical Officer, Executive Vice President, Intra-Cellular Therapies, Andrew Elias, Director - Global Regulatory Affairs, Johnson and Johnson, Trent Fowler, Associate Director Early Phase Translational Medicine, Otsuka , Zhanyan Fu, Associate Director, The Broad Institute of MIT and Harvard, James Gilligan, President and Chief Executive Officer, TRYP Therapeutics, Alex Goddard, Director MSRD, Otsuka, Matt Harlin, Senior Director - Discovery Research, Early Phase and Translational Medicine, Otsuka, Odette Hauke, Regulatory Affairs Consultant, ATAI Life Sciences, Nanco Hefting, Chief Specialist, Lundbeck, William Horan, Clinical Science Program Lead, Neuropsychiatry, Bristol Myers Squibb, Allison House-Gecewicz, Senior Vice President and Head of Clinical Operations Research, Cybin, Steven Hyman, Professor of Stem Cell and Regenerative Biology, Harvard Medical School, Jacob Jacobsen, Chief Executive Officer, Evecxia Therapeutics , Jamileh Jemison, Medical Director, Clinical Development, MindMed, Matthew Johnson, Senior Group Leader, The Broad Institute of MIT and Harvard, Namik Kirlic, Director - Clinical Care Research, COMPASS Pathways, Aaron Koenig, Chief Medical Officer, Delix Therapeutics, Amy Kruse, Chief Investment Officer, Satori Capital, Matthew Kuntz, Neuroscience Vice President, Global Regulatory Affairs Legal, Abbvie , Johan Luthman, Executive Vice President and Head of R AND D, Lundbeck, Snezana Milanovic, Senior Medical Director, Clinical Development, Neumora Therapeutics, Silke Miller, Distinguished Scientist - Translational Sciences, Johnson and Johnson , Janet Nicholson, Global Asset Lead - CNS Diseases and Translational Medicine, Boehringer Ingelheim , Christopher Ocampo, Group Medical Director, Psychiatry, Abbvie , David Olson, Chief Innovation Officer, Delix Therapeutics, Mark Pollack, Chief Medical Officer, Reunion Neuroscience, Abhishek Pratap, Executive Director, Global Evidence Lead, Boehringer Ingelheim, David Ruhl, Principal Scientist - Translational R AND D, Neurocrine Biosciences, Natalie Sacks, Venture Partner, Novo Holdings, Jackie von Salm, Co-Founder and Chief Scientific Officer, Psilera Bioscience, Colin Sauder, Chief Scientific Officer, Adams Clinical, Liam Scott, Senior Director, Neumora Therapeutics, Kevin Spencer, Associate Professor of Psychiatry, Harvard Medical School , Krishna Vadodaria, Director, Engrail Therapeutics , Chris Weyrer, Principal, Vida Ventures, Nurulain Zaveri, President and Chief Scientific Officer, Astraea Therapeutics